The Role of Aldosterone & Aldosterone Synthase Inhibitors in Cardiology, with Javed Butler, MD, MBA

Aldosterone is drawing renewed scientific attention as a treatment target across heart failure, chronic kidney disease, and resistant hypertension. A new generation of aldosterone synthase inhibitors aims to lower aldosterone production directly, rather than blocking its receptor.

In an interview at the 10th Annual Heart in Diabetes Meeting, Javed Butler, MD, MBA, president of the Baylor Scott & White Research Institute, examined where this approach fits in cardiorenal care. He weighed the evidence behind aldosterone synthase inhibition and its potential role in guideline-directed medical therapy for heart failure.

Recapping a session he led at the meeting, Butler emphasized how earlier aldosterone modulation data came largely from heart failure with reduced ejection fraction, along with post-myocardial infarction trials in reduced ejection fraction and heart failure. Noting evidence in chronic kidney disease and in prevention lagged, and findings in heart failure with preserved ejection fraction were contested.

Butler highlighted the unresolved question remains whether the aldosterone hypothesis itself is flawed or whether current receptor-targeted therapies leave meaningful residual benefit unharnessed. Lowering aldosterone levels directly through synthase inhibition offers a way to test the second possibility.

When asked on choosing between mineralocorticoid receptor antagonists and aldosterone synthase inhibitors, Butler highlighted this debate remains unsettled until further trial data becomes available. He called attention to earlier MRA trials enrolling few patients on SGLT2 inhibitors or GLP-1 receptor agonists, whereas the synthase inhibitor trials use active comparators in which every participant receives an SGLT2 inhibitor.

References:

ClinicalTrials.Gov. A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure (LUMINARA). Clinicaltrials.gov. Published February 18, 2026. Accessed June 21, 2026. https://clinicaltrials.gov/study/NCT06299826